---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-24-035864"
form_type: "8-K"
ticker: "FHTX"
cik: "0001822462"
company_name: "Foghorn Therapeutics Inc."
filed_at: "2024-08-08T23:59:59+00:00"
generated_at: "2026-05-31T11:10:33.627236+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Foghorn reports Q2 net loss $23M; cash $285M into 2027; FHD-286 AML data Q4; FHD-909 first patient H2 2024

## Summary
- Net loss $23.0M for Q2 2024 vs $29.5M in Q2 2023; collaboration revenue $6.9M.
- Cash, equivalents & marketable securities $285.2M as of June 30, 2024; expected cash runway into 2027.
- Topline Phase 1 data for FHD-286 + decitabine in r/r AML anticipated Q4 2024; includes safety, efficacy, PK/PD.
- FHD-909 (SMARCA2 selective inhibitor) IND cleared May 2024; first patient dosing H2 2024 in SMARCA4 mutated NSCLC.
- Selective CBP degrader IND-enabling studies on track to start Q4 2024; $110M financing closed May 2024.

## SEC filing metadata
- accession: 0001628280-24-035864
- form_type: 8-K
- ticker: FHTX
- cik: 0001822462
- company_name: Foghorn Therapeutics Inc.
- filed_at: 2024-08-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1822462/000162828024035864/0001628280-24-035864-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1822462/000162828024035864/fhtx-20240808.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-24-035864
- JSON: https://secwatch.observer/filing/0001628280-24-035864.json
- Plain text: https://secwatch.observer/filing/0001628280-24-035864.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.